Facidase Injection
Hyaluronidase
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Facidase Injection is used for:
Hypodermoclysis, Facilitate SC/IM inj, Aid in dispersal of extravasated fluids or blood, Aid in diffusion of local anesthesia in ophthalmology
Adult Dose
Skin Test
0.02 (3 units) of 150 units/mL solution intredermally; a wheal with pseudopods appearing within 5 min and persisting for 20-30 min with itching will indicate positive hypersensitivity reaction
Absorption/Dispersion of Injected Drugs
Add 50-300 units (typically 150 units) to the injection solution
Hypodermoclysis
Amphadase/Hylenex: Inject 150 units prior to SC fluid administration; this will facilitate absorption of 1000 mL or more of solution
Vitrase: Inject 200 units prior to SC fluid administration; this will facilitate absorption of 1000 mL or more of solution
Adjunct Subcutaneous Urography
Improves resorption of radiopaque agents; indicated when intravenous administration cannot be successfully accomplished, with the patient prone
Inject 75 units SC over each scapula, followed by injection of the contrast medium at the same sites
Child Dose
Skin Test
0.02 (3 units) of 150 units/mL solution intradermally; a wheal with pseudopods appearing within 5 min and persisting for 20-30 min with itching will indicate positive hypersensitivity reaction
Hypodermoclysis
Children > 3 years: May be added to small volumes of solution (up to 200 mL), such as or solutions of drugs for SC injection
Infants and children < 3 years: Volume of a single clysis should be limited to 200 mL
For premature infants or during the neonatal period: Do not exceed a daily dosage of 25 mL/kg of body weight; rate of administration should not be greater than 2 mL/min
Adjunct in Subcutaneous Urography
Used when IV administration cannot be successfully accomplished, particularly in infants and small children, with the patient prone
Inject 75 units SC over each scapula, followed by injection of the contrast medium at the same sites
Renal Dose
Administration
Contra Indications
Hypersensitivity, malignancy. Direct application to the cornea, reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.
Precautions
Impaired renal function. Infants, elderly. Patients with infections. Pregnancy, lactation.
Lactation: It is not known whether hyaluronidase is excreted in human milk; caution should be exercised
Pregnancy-Lactation
Interactions
Action potentiated by urokinase especially in the treatment of MI. May increase absorption and toxicity of local anaesthetics. Heparin, salicylates and NSAIDs may inhibit the spreading action and efficacy of hyaluronidase.
Adverse Effects
Side effects of Hyaluronidase :
<1%
Angioedema, urticaria, allergic reactions (<0.1%)
Frequency Not Defined
Edema,Local injection site reactions
Potentially Fatal: Hypersensitivity and anaphylaxis.
Mechanism of Action
Hyaluronidase is an enzyme which reduces the viscosity of ground substance, thus making the tissues more permeable to injected fluids. It facilitates distribution and absorption of locally injected substances. It also promotes resorption of excess fluids and extravasated blood in the tissues.
Note
Facidase Injection manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Hyaluronidase. Facidase is availble in Nepal.
Farmaco Nepal drug index information on Facidase Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.